Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
{{output}}
Radium-223 dichloride (Ra-223) is the first α-particle emitting radiopharmaceutical to be approved for the treatment of patients with castration-resistant prostate cancer and associated bone metastases, and the first bone-targeting agent to significantly impr... ...
